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respectively. Ustekinumab 45mg&90mg -treated patients achieved greater 
improvements in patient assessment of pain (25.9% &29.6% vs. 4.5%, P<0.001), 
patient assessment of disease activity (25.4% &27.6% vs. 7.6%, P<0.001)& greater 
reduction in impact of disease on work productivity (1.82& 2.64 vs. 0.78, P<0.001) 
versus PBO-treated patients, respectively. CONCLUSIONS: Ustekinumab 
improves general as well as arthritis &skin-related QoL, &reduces the impact of 
disease on work productivity in patients with active PsA.  
 
PMS55  
A EUROPEAN ASSESSMENT OF THE IMPACT OF INADEQUATE PAIN RELIEF (IPR) 
ON HEALTH-RELATED QUALITY OF LIFE (QOL) IN PATIENTS WITH KNEE 
OSTEOARTHRITIS (OA) IN THE SURVEY OF REAL WORLD THERAPIES (SORT)  
Black CM1, Stokes L2, Phillips C3, Peloso PM4, Mavros P4, Everett SV4, Moore A5, Conaghan 
P6, Sen S4, Taylor SD4 
1St. John's University, Queens, NY, USA, 2Merck & Co., Inc., Whitehouse Station, NJ, USA, 3Swansea 
University, Swansea, Wales, UK, 4Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 
Whitehouse Station, NJ, USA, 5Oxford University, Oxford, UK, 6University of Leeds, Leeds, UK  
OBJECTIVES: To describe inadequate pain relief (IPR) and evaluate its impact on 
QOL in patients with knee osteoarthritis. METHODS: SORT, a 12-month 
prospective study across 6 EU countries (N=1,260), enrolled participants >50 years 
old with knee OA who were prescribed pain medications. Clinical history and 
QOL (generic and disease-specific) were collected at baseline and months 1, 3, 6, 
9 and 12. Inadequate Pain Relief (IPR) was defined as a Brief Pain Inventory (BPI) 
pain score of "moderate or greater pain" (score >4). Statistical analyses of 
baseline data were conducted. RESULTS: Evaluable baseline data are presented 
for 1217 participants: 67.6% women; mean age 68 (SD=9.4) years; mean duration 
of OA 5.9 years (SD=6.2) and 83.4% reported taking oral pain medications. IPR 
comprised 54% of the cohort (656 of 1217). IPR participants reported more 
disability (14.3% vs. 9.3%, p=0.013), greater number of co-morbidities (p<0.0001) 
and were taking more opioid-containing medications (27.1% vs. 16.3%, p<0.001) 
than those with pain relief. IPR participants had worse WOMAC scores: stiffness 
(56.9 vs. 33.6, p<0.001), pain (53.2 vs. 28.4, p<0.001) and physical function (54.9 vs. 
29.9, p<0.001). IPR participants reported significant worse scores for pain severity 
(5.8 vs. 2.7, p<0.001) and pain interference (5.3 vs. 2.4, p<0.001) as measured by 
BPI. General health status was lower for IPR participants with 51.2% vs. 29.0% 
(p<0.001) reporting fair/poor health. IPR participants scored worse on all SF-12 
domains with differences for the physical component summary (PCS) (35.1 vs. 
41.4, p<0.001) and mental component summary (MCS) (45.7 vs. 52.0, p<0.001). 
CONCLUSIONS: SORT found over half of participants reported inadequate pain 
relief (i.e., moderate to severe pain). IPR participants experienced more co-
morbidities and significant QOL impairments as demonstrated by poorer health 
status, greater pain, physical limitations and stiffness than participants with 
pain relief. The presented SORT baseline data support the relationship between 
IPR and reduced QOL.  
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OBJECTIVES: International Osteoporosis Foundation Quality of Life questionnaire 
(QUALEFFO-41) is the specific questionnaire for the postmenopausal women 
with osteoporosis and vertebral fractures. Reliability of the questionnaire could 
be confirmed by sensitivity and specificity. The objective of this stidy is to test 
the sensitivity and specificity of the QUALEFFO-41 questionnaire. METHODS: A 
case-control study was conducted during the period of June 2010 - October 2011 
to test the main characteristics of the questionnaire. The study included 100 
patients with osteoporosis (50 cases with vertebral fractures and 50 controls 
without fractures). The questionnaire EQ-5D (with direct-scoring) was used for 
comparison of the results with the QUALEFFO-41 (with reverse-scoring). The 
study was performed in two medical centers in Serbia. RESULTS: The results of 
the ROC curve analysis (between the case and control group of patients) 
indicated that the AUC ranges for all five dimensions of the QUALEFFO-41 
questionnaire and the total score were 0.62–0.69. The QUALEFFO-41 had a better 
prediction of the value of HRQOL of cases compared to the generic questionnaire 
EQ-5D (the AUC difference of the total scores was 0.099, p=0.013). Correlations 
between the total scores of the QUALEFFO-41 and the EQ-5D health state value, 
for both groups, were negative and statistically significant (r=-0.78, p<0.001 and r 
= -0.73, p<0.001, respectively). CONCLUSIONS: The QUALEFFO-41 has the ability 
to detect the patients with osteoporosis and vertebral fractures among the 
osteoporosis patients. This questionnaire is more specific for the osteoporosis 
patients with fractures in relation to the EQ-5D questionnaire.  
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OBJECTIVES: To explore the personal experiences of Korean elderly women who 
have sustained osteoporotic fragility fractures regarding their disease and 
treatment burdens. METHODS: The research design was a qualitative descriptive 
study. Open-ended questions were asked of twelve Korean elderly women who 
experienced at least two osteoporotic fractures. They participated in an in-depth 
face-to-face interview. Data were analyzed using qualitative content analysis 
method, which is an inductive process following eight steps developed by Downe-
Wamboldt. RESULTS: Five themes were identified: 1) physically living with pain and 
disability following unexpected fractures; 2) financially facing a penniless old age 
and unaffordable treatment cost; 3) emotionally feeling the unbridgeable gap 
between desired life and the present; 4) cognitively having health illiteracy and 
medical ignorance; and 5) socially and spiritually copying with pain and trying to be 
free from their suffering lives. CONCLUSIONS: The interview participants described 
how they have suffered from chronic pains and a dysfunctional body after 
unexpected and recurrent fractures, which made their quality of life decrease. Since 
most women in this older generation have had low educational attainment and 
minimal financial preparations for their retirement years, they perceive the medical 
treatment cost of osteoporosis and their dependency on their own adult children as 
burdens. Therefore, Korean health care policy stakeholders and professionals need 
to develop medical assurance and osteoporotic fracture disease specific guidelines 
that are tailored to this generation.  
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OBJECTIVES: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on productivity of paid and household work, and daily activities, in 
psoriatic arthritis (PsA). METHODS: Patients had active PsA and had failed ≥1 
DMARD. Patients were randomized 1:1:1 to placebo, or CZP 400mg at Week (Wk) 
0, 2 and 4 followed by either 200mg CZP every 2 weeks (Q2W) or 400mg CZP every 
4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS, 
administered Q4W) was used to assess the impact of PsA on productivity at 
work, at home and daily activities. WPS responses (LOCF imputation) were 
compared between treatment arms using a non-parametric bootstrap-t method. 
RESULTS: A total of 409 patients were randomized. 56.6%, 60.1%, and 61.5% of 
patients in the placebo, CZP 200mg Q2W, and CZP 400mg Q4W groups were 
employed outside home at study baseline. Baseline workplace and household 
productivity was comparable between treatment arms. At baseline, PsA 
impacted workplace absenteeism, and presenteeism; however, PsA burden on 
household productivity and participation in social activities was greater. 
Compared to placebo, employed patients in both CZP groups reported a greater 
decrease in absenteeism (mean 1.6 vs. 0.2 and 0.6 days per month) and 
presenteeism (mean 3.5 vs. 1.3 and 2.1 days per month) at Wk24. Improvements 
were observed as early as Wk4. CZP groups also reported larger improvements in 
household productivity as early as Wk4 and continued up to Wk24, compared to 
placebo. CONCLUSIONS: CZP improved workplace productivity in patients with 
PsA by reducing absenteeism and presenteeism. CPZ also improved household 
productivity and increased participation in social and daily activities.  
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OBJECTIVES: Investigate the effect of certolizumab pegol (CZP), a PEGylated Fc-
free anti-TNF, on paid and household work productivity, and daily activities, in 
patients with axial spondyloarthritis (axSpA), including patients with ankylosing 
spondylitis (AS) and non-radiographic axSpA (nr-axSpA, axSpA with no 
definitive sacroiliitis on X-ray). METHODS: Recruited patients had adult-onset 
active axSpA, including AS and nr-axSpA. Patients were randomized 1:1:1 to 
placebo, or CZP 400mg at Week (Wk) 0, 2 and 4 followed by either CZP 200mg 
every two weeks (Q2W) or CZP 400mg every four weeks (Q4W). The arthritis-
specific Work Productivity Survey (WPS, administered Q4W) assessed the impact 
of axSpA on workplace and household productivity. WPS responses (LOCF 
imputation) were compared between treatment arms using a non-parametric 
bootstrap-t method. RESULTS: A total of 325 patients were randomized. At 
baseline, 63.2%, 69.4%, and 74.8% of placebo, CZP 200mg Q2W, and CZP 400mg 
Q4W group patients were employed outside the home. Baseline workplace and 
household productivity was similar between groups. Baseline burden of axSpA 
on workplace and household productivity was high. Compared to placebo, 
employed patients in CZP 200mg Q2W and 400mg Q4W groups reported reduced 
absenteeism (mean 2.0 vs 1.1 and 0.6 days per month) and presenteeism (mean 
4.4 vs 2.4 and 2.7 days per month) at Wk24. Improvements were observed as 
early as Wk4. CZP groups reported greater reductions vs placebo in lost days of 
household work and of family/social/leisure activities per month, in days with 
reduced household productivity and in axSpA interference with household 
duties as early as Wk4 through to Wk24. Similar improvements were reported in 
both AS and nr-axSpA populations. CONCLUSIONS: CZP improved workplace 
productivity in patients with axSpA by reducing absenteeism and presenteeism. 
